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Programmable nucleases allow defined alterations in the genome with ease-of-use, efficiency 
and specificity. Their availability has led to accurate and widespread genome engineering, with 
multiple applications in basic research, biotechnology and therapy. With regards to human 
gene therapy, nuclease-based gene editing has facilitated development of a broad range of 
therapeutic strategies based on both non-homologous end-joining and homology-dependent 
repair. This review discusses current progress in nuclease-based therapeutic applications for a 
subset of inherited monogenic diseases including cystic fibrosis, Duchenne muscular dystrophy, 
diseases of the bone marrow and haemophilia, and highlights associated challenges and future 
prospects. 
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INTRODUCTION 
There are five-eight thousand monogenic diseases, defined as inherited conditions arising from 
mutations on a single gene1. These often manifest during childhood and lead to morbidity and 
sometimes premature death. While each monogenic disease is rare, it has been estimated that 
together they will affect about 6% of people at some point in their lives1. Diagnosis and 
treatment for these diseases remain largely insufficient and the care is primarily palliative, 
focusing on disease management without addressing the underlying genetic defects. The 
realisation of the social and economic importance of rare diseases and the acute need for 
diagnostics and treatments has led to initiatives like the International Rare Disease Research 
Consortium (IRDiRC, http://www.irdirc.org), the Undiagnosed Diseases Network (UDN, 
http://www.genome.gov/27562471) and Syndromes Without a Name UK (SWAN UK, 
http://www.geneticalliance.org.uk/projects/swan.htm). 
Gene therapy, which encompasses a range of strategies, aimed from the outset to treat 
inherited disorders, assuming that monogenic diseases would be the easiest to target. Classical 
gene therapy approaches have centred on the delivery of DNA to augment endogenous gene 
expression. Predominantly, these approaches rely on the transfer of functional genes using a 
variety of viral vectors, due to their intrinsic ability to effectively transduce human cells. 
Retroviral vectors provided the first clear demonstrations of therapeutic benefit in primary 
immunodeficiencies, and they also highlighted the risk of adverse events attributable to 
insertional mutagenesis due to genomic integration of proviruses2. Among several, other 
success stories include Glybera3, the first clinically approved gene therapy in the EU, which uses 
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an adeno-associated virus (AAV) vector drug for lipoprotein lipase deficiency; and in the case of 
cystic fibrosis, repeated nebulisation of liposomes encoding the cystic fibrosis transmembrane 
conductance regulator (CFTR) gene has shown some therapeutic benefit4. Thus gene 
augmentation shows great therapeutic promise and has set the stage for the gene-editing 
approaches reviewed here. 
Gene editing is a gene therapy approach that relies on designer nucleases to recognise and cut 
specific DNA sequences, and subsequently exploits innate cellular DNA repair pathways, namely 
non-homologous end joining (NHEJ) and homology directed repair (HDR), to introduce targeted 
modifications in the genome (Fig. 1a). Four nuclease families have been used in this context: 
meganucleases (MGNs), zinc-finger nucleases (ZFNs), transcription activator-like effector 
nucleases (TALENs) and clustered regulatory interspaced short palindromic repeats associated  
RNA-guided Cas9 (CRISPR-Cas9) nucleases5. These can be designed to precisely introduce a 
double stranded break (DSB) at the target locus of interest. The DSB will then be repaired by 
either NHEJ or HDR. NHEJ involves direct ligation of DNA ends in a highly efficient but error-
prone manner, which causes small insertions and/or deletions (Indels) at the break site. In the 
context of a disease-causing locus, NHEJ can be exploited to excise or disrupt deleterious 
sequences, or even restore the reading frame of a gene (Fig. 1b). In contrast, HDR requires a 
donor DNA containing sequences homologous to those adjacent to the DSB. The donor DNA 
can be used to repair a mutation, or to knock-in a block of exons (“superexon”) or a full cDNA at 
either the endogenous locus (reconstituting the wild-type sequence) or at a genomic ‘safe 
harbour’ (a region of DNA where transgenes can integrate and express in a predictable manner 
without insertional mutagenesis or perturbation of gene function)6 (Fig.1b). Gene editing thus 
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opens up the possibility of permanently modifying a genomic sequence of interest by enabling 
targeted disruption, insertion, excision, and correction in both ex vivo and in vivo settings (Fig. 
1c). Whilst these advances are expected to revolutionise the field at large, current gene editing 
approaches are limited by efficacy of modification, safety concerns related to the specificity of 
nucleases and delivery of gene editing tools to target cell types. This review aims to outline 
prominent gene editing research across a range of monogenic disorders (Table 1), and to 
highlight recent advancements and current challenges.  
 
GENE EDITING IN MONOGENIC DISORDERS 
CYSTIC FIBROSIS  
Cystic Fibrosis (CF) is an autosomal recessive disease resulting from mutations in the CFTR gene, 
which encodes an epithelial anion channel. CFTR is distributed across a wide range of organs 
including pancreas, kidney, liver, lungs, gastrointestinal and reproductive tracts, making CF a 
multi-organ disease. Mutations in CFTR lead to sub-optimal ion transport and fluid retention, 
causing the prominent clinical manifestations of abnormal thickening of the mucus in lungs and 
pancreatic insufficiency7. In the lung, dysfunctional CFTR hinders mucociliary clearance, 
rendering the organ susceptible to bacterial infections and inflammation, ultimately leading to 
airway occlusion, respiratory failure and premature death8. CF remains the most common and 
lethal genetic disease among the Caucasian population with 70,000–100,000 sufferers 
estimated worldwide, highlighting a real need for the development of better treatments.  
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One major challenge to the development of a therapeutic strategy for CF is the huge diversity 
of mutation types. ΔF508 (deletion of phenylalanine at codon 508) mutation, with a prevalence 
of >80% in CF patients, is by far the most common but more than 1,990 CFTR-mutations have 
been described9. They cause premature stop codons, aberrant splicing, incorrect protein folding 
or trafficking to the cell surface, and dysfunctional CFTRs with limited channel opening 
capacity9. Pharmacological interventions have been targeted to several of these processes, in 
the form of: (i) read-through therapeutics, which recognise premature stop codons, thereby 
allowing full-length protein production and a decline in associated nonsense-mediated decay10; 
(ii) correctors, which enable slightly misfolded proteins to evade endoplasmic reticulum quality 
control and insert at the primary epithelia11; and (iii) potentiators, which target gating 
mutations and increase channel opening8,12. One prominent drug, the potentiator Ivacaftor 
(Kalydeco), has demonstrated significant improvement of numerous clinical endpoints such as 
forced expiratory volume (FEV), weight gain, reduction of hospital admissions (related to 
requirement of IV antibiotic administration) and increase in lung clearance index in diverse 
patient subsets bearing the G551D-CFTR missense mutation13–16. Ivacaftor also demonstrated 
clinical benefit in other gating mutation types: G1244E, G1349D, G178R, G551S, G970R, 
S1251N, S1255P, S549N and S549R, with G970R being one exception17. In the case of ΔF508, 
ivacaftor has been tested in a Phase 3 clinical trial in combination with lumacaftor18. The 
improvements seen in FEV were modest compared to ivacaftor monotherapy in G551D 
studies13,15. Thus, while drug administration is therapeutic in some gating mutation types, the 
commonly occurring ΔF508 still requires a more effective treatment. QR-010 is a drug based on 
modified single stranded RNA and designed to repair ΔF508 mRNA; research in human cell lines 
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and mice appears promising and is currently progressing to a phase 1b clinical trial19,20. 
However, this still would not address mutations resulting from aberrant splicing; it is in these 
instances gene editing could prove most beneficial. 
The premise of permanent correction by gene-editing, as opposed to drug and recent non-viral 
gene therapy treatments (previously reviewed9,21) which require repeated administration, is 
promising. Such CFTR correction at the genome level has been trialled across many of the gene-
editing platforms. ZFNs were first used to achieve HDR-mediated knock-in of a 4.5 kb genomic 
donor harbouring CFTR exons 10-24. The efficiency in patient-derived epithelial cells was 
modest, with DNA cleavage as measured by NHEJ estimated at 7.8% and the subsequent HDR 
occurring at <1%, respectively22. The ΔF508 mutation was targeted and functional repair 
obtained in stem cell organoids, using CRISPR-Cas9-mediated HDR and an exon 11 and 
puromycin resistance-containing DNA donor. In most instances, this resulted in a heterozygous 
phenotype or mono-allelic correction. Moreover, the forskolin-induced swelling assay, which 
demonstrates functional correction of the organoids via fluid secretion into the epithelia, 
showed more improvement than chemical correctors23,24. Although for stem cell organoids 
there are colon engraftment data, extension of these studies to lung would be helpful to assess 
the therapeutic promise of this approach25. Similar HDR strategies have demonstrated CFTR 
correction in induced pluripotent stem cells (iPSCs) derived from CF patients, bearing 
heterozygous ΔF508/ΔI507 mutations in the ZFN study26; and Δ508 homozygous mutations in 
the TALENs27 as well as Cas928 studies. Genetically modified iPSCs can be selected and amplified 
at clonal level, allowing the production of pure populations of corrected cells, something 
unlikely to be achieved with primary cells. Two of these reports demonstrated that corrected 
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clones could be differentiated successfully into epithelial cells, whilst retaining CFTR 
expression26,27. Even with these advances, the multi-organ involvement of CF would limit an ex 
vivo approach as engraftment of corrected cells would only provide localised correction. In 
addition, there is a lack of consensus regarding which cells of the sinuses and lungs should be 
targeted in the amelioration of CF. 
Given that drug therapy has demonstrated moderate repair, the focus may now be upon 
reaching a therapeutic threshold. Current threshold estimates are in the range of 10-24% of 
normal expression9, similar to improvements in FEV following the use of ivacaftor9, and perhaps 
achievable for other mutations by a combination of gene and drug therapies. The development 
of a catalytically inactive Cas9 in which the DNA cleavage domains harbour point mutations, 
tethered to a VP64 transcriptional activator, could be used to upregulate CFTR expression29,30. 
This transcriptional enhancement of the mutant gene, coupled to corrector and potentiator 
therapy, could be beneficial as the pool of protein available to be inserted within the epithelial 
surface would be increased. 
 
DUCHENNE MUSCULAR DYSTROPHY  
Duchenne muscular dystrophy (DMD) is an inherited X-linked disease resulting from mutations 
that disrupt the reading frame in the gene encoding dystrophin. This protein plays a crucial role 
in stabilisation of muscle sarcolemma and signalling. In the absence of dystrophin, progressive 
muscle wasting, with concomitant declines in respiratory and cardiac function occur. Over time, 
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this results in the loss of ambulation, necessitates the use of invasive ventilation, and ultimately 
leads to premature death31,32.  
Presently, there is no effective treatment for DMD. Current interventions including the use of 
prednisolone are inadequate, targeting only secondary characteristics of inflammation and 
muscle loss33. Despite being recognised as a prime candidate for gene therapy since the 
discovery of DMD in 1987, advancement has been hindered because DMD is the largest 
naturally occurring gene, spanning 2.5 Mb, with a cDNA of 11.2 Kb. A great deal of work has 
focused upon mutation-specific strategies using pharmacological and gene therapy approaches. 
Many of the current approaches, such as exon skipping, aim to restore the reading frame by 
targeting mRNA, masking splice sites or enhancers of exons that shift the reading frame34,35. 
The aim of these strategies is to produce a truncated but viable dystrophin protein, resulting in 
a clinically milder Becker rather than Duchenne muscular dystrophy phenotype36. 
Genome editing approaches for DMD include promoting permanent exon removal37, and HDR-
mediated cDNA knock-in38,39. Notable demonstrations in primary patient myoblasts have been 
the permanent excision of exon 51 (which would be applicable to 13% of patients) achieved 
using ZFNs, leading to restoration of the reading frame in an approach akin to exon skipping40, 
and permanent removal of exons 45-55 by multiplexed Cas9 (Fig. 1b). The latter is a mutational 
hotspot which if targeted could be therapeutically applicable for 62% of patients37. Both of 
these approaches result in a truncated but functional dystrophin protein41. The mutational 
hotspot has also been targeted by HDR, with meganuclease-mediated repair of exons 45-52 in 
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immortalised patient cells38. The benefit of the HDR-mediated approach is that the subsequent 
correction would enable the restoration of full-length dystrophin (Fig. 1b). 
DMD has also been restored by genome editing in iPSCs from a patient lacking exon 44 by three 
different strategies: exon 45 skipping by disruption of its splicing acceptor, Indel-mediated 
frameshift of exon 45, and exon 44 knock-in, utilising both TALEN and CRISPR-Cas9 
approaches39. Targeted differentiation of such iPSCs could eventually progress to correction of 
individual mutation types via engraftment of corrected proliferative cells into muscles. Some 
concerns with this approach are the modulation of cell proliferation, efficiency of the 
engraftment process and localised intramuscular regeneration42. 
Model systems are also providing data of relevance to human therapy. Direct germline 
correction of a murine Dmd mutation has recently been demonstrated in the mdx mouse, in 
which the exon 23 nonsense mutation was corrected via Cas9 mRNA injection followed by 
implantation into pseudo pregnant females. This resulted in mosaicism within targeted animals, 
showing correction ranging from 2-100%; this type of work could establish the level of 
dystrophin expression required to provide therapeutic benefit, which is currently predicted to 
be between 15-20%43. Two genotypically distinct rat models have also been produced, one with 
a C>T nonsense mutation in exon 23 analogous to that of the mdx mouse, and another with a 
large deletion spanning exons 6-1344,45. Additionally, the use of CRISPR-Cas9 in pigs and non-
human primates for the generation of DMD phenotypes, demonstrates that such gene-editing 
can be easily transitioned into larger animals46–48. This ease of generation of new DMD animal 
models allows for a range of mutation types to be produced, thereby providing a greater 
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diversity of models for translational research. Moreover, larger animal models such as rats, pigs 
and primates tend to exhibit muscle phenotypes such as fibrosis, which is more representative 
of the clinical manifestations seen in patients than those in the commonly used mdx mouse49,50. 
Thus, such models could serve to enrich our understanding of DMD at large and produce more 
robust and reliable end-points to determine efficacy of treatments. 
 
DISORDERS OF THE BONE MARROW  
Bone marrow diseases comprise a variety of conditions including severe anaemic 
haemoglobinopathies and over 250 different primary immunodeficiencies (PIDs). Current 
treatment modalities include transfusion of blood, or blood-derived products such as 
erythrocytes, immunoglobulins and platelets. However, haematopoietic stem cell (HSC) 
transplantation remains the only curative therapy to achieve permanent reconstitution. Despite 
the growing number of donor depositories, a human-leukocyte-antigen matched donor cannot 
be found for some patients. In these cases gene therapy using gene addition in autologous 
patient cells may offer a potentially safe and efficacious strategy. Successful and durable 
reconstitution using retroviral and/or lentiviral vectors has been achieved in patients suffering 
with various bone marrow disorders, including X-linked severe combined immunodeficiency 
(SCID-X1)2,51,52, adenosine deaminase (ADA) deficiency53–57, Wiskott-Aldrich syndrome58,59, and 
β-thalassemia60,61. 
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Haemoglobinopathies: Beta-thalassemia and sickle cell anaemia  
Haemoglobinopathies or ‘genetic anaemias’ result from defects of mature haemoglobin. Both 
β-thalassemia and sickle cell anaemia (SCA) are caused by mutations on the HBB gene which 
encodes the β-globin chain. β-thalassemias are heterogeneous, with >200 mutation types 
across the HBB locus affecting different steps of β-globin production (initiation of transcription, 
splicing, and post-translational modification). The subsequent excess of α-globin causes 
apoptosis of red blood cells (RBCs) resulting in severe anaemia. In contrast, SCA is caused by a 
missense mutation (A-to-T transversion) at codon 6 of HBB, which causes RBCs to distort to a 
‘sickle’ shape. Sickled RBCs constrict small capillaries causing severe tissue damage, acute 
painful crises, respiratory insufficiency and progressive organ damage62. SCA is one of the most 
common monogenic diseases with over 250,000 cases every year and is a major cause of 
morbidity and mortality worldwide63. 
Although non-targeted gene augmentation for haemoglobinopathies has made considerable 
progress60,61,64, the high levels of gene expression required and the potential risk of insertional 
mutagenesis associated with uncontrolled viral integration remain challenging. Editing the HBB 
locus using programmable nucleases can instead allow for permanent β-globin correction. 
Recently, TALENs were used to achieve ~20% HDR-mediated knock-in of therapeutic β-globin 
full-length cDNA to the endogenous β-globin locus in K562 erythroleukemia cells65. Such a 
strategy would result in expression of β-globin from the cDNA instead of wild-type genomic 
sequence and would be therapeutic for both SCA and β-thalassemia. Separately, ZFNs were 
used to repair the SCA point mutation in CD34+ HSC progenitor cells (HSPCs). Co-delivery of ZFN 
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mRNA and a donor template led to 15% and 18% HDR in CD34+ cells derived from healthy-
donor and patients with SCA, respectively66. Furthermore, correction of SCA mutation in patient 
cells led to production of wild-type haemoglobin in vitro. As only 10-30% of corrected donor 
cells are required to generate sufficient RBCs, gene repair in HSCs obtained from patients can 
reach a therapeutic threshold66.  
Another strategy being explored in the context of haemoglobinopathies is gene editing of 
disease-causing mutations in iPSCs. These can be differentiated into HSCs, which can then be 
used for autologous transplantation. Recently, independent groups have demonstrated 
progress in this area by applying ZFNs67, TALENs68 or Cas968,69 to correct different β-thalassemia 
mutations in various patient iPSCs. Corrected iPSCs maintained their ability to differentiate into 
erythroblasts with increased transcription of β -globin69. Similar progress has also been made 
for SCA where ZFNs70 and TALENs71 were used to repair the sickle cell point mutation in patient 
iPSCs. For treatment of sickle cell disease, it is particularly important to ensure that the highly 
paralogous genes encoding gamma-globin and delta-globin are not inadvertently mutagenized. 
Both studies specifically analysed these loci and demonstrated no nuclease-associated off-
target activity. These studies demonstrate that human stem cells including HSCs and iPSCs, and 
nuclease-induced gene editing approaches can be used in combination to create corrected 
patient-derived cells. Despite the many advantages of iPSC technology, for immune-based 
therapy potential concerns of immunogenicity in iPSC and its derivatives should be thoroughly 
examined before clinical translation72. 
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Apart from adult haemoglobin, the level of foetal haemoglobin (HbF) is also a key modifier of 
clinical severity of haemoglobinopathies. In patients with SCA, high HbF is associated with 
generally milder disease phenotype. This has been attributed to naturally occurring variants in 
the enhancer regions of BCL11A, a transcriptional repressor of HbF production in adult 
erythroid cells73. Recently, TALENs/ZFNs74 and Cas9-nuclease75 were used to specifically disrupt 
enhancer regions in BCL11A resulting in substantial HbF induction without the detrimental 
effects associated with complete loss of BCL11A. Such therapeutic gene editing approach could 
be used to elevate HbF to clinically relevant levels thereby ameliorating β haemoglobin 
disorders. 
 
Primary immune deficiencies  
Primary immune deficiencies comprise a heterogeneous group of rare diseases in which part of 
the immune system is missing or functions improperly. On the clinical spectrum, severe 
combined immunodeficiency (SCID) is the most severe form of PID, resulting in a development 
block in production of T-cells, with additional defects of B- and natural killer cells. The most 
common form of SCID, SCID-X1, is caused by mutations in the gene encoding the interleukin 2 
receptor common gamma chain (IL2RG). Several groups have successfully used ZFNs to target 
and induce HDR in the IL2RG locus in human HSCs and embryonic stem cells, albeit with 
relatively low efficiencies76–78. A notable demonstration was the ZFN-mediated insertion of 
corrective cDNA (exons 5-8 that would correct all SCID-X1 mutations downstream of exon 4) 
into the IL2RG mutational hotspot in long-term repopulating HSCs. This led to the correction of 
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defective IL2RG in HSPCs from a subject with SCID-X1 and multi-lineage differentiation upon 
transplantation into immunodeficient SCID mice78. Separately, TALENs were used to specifically 
target and induce HDR in the IL2RG locus of Jurkat cells79.  
While direct genome editing in HSCs is an attractive alternative to viral gene addition therapy, 
both approaches are dependent on the capability to efficiently culture and expand HSCs ex vivo. 
In addition, HSC-based transplantation approaches generally involve myeloablative 
conditioning, which given the young age and immunocompromised state of SCID patients, 
poses significant risk. An iPSC-based approach could provide an unlimited source of subject-
derived, corrected cells from which immune cells could be derived continuously for transfusion, 
but it would be a cumbersome approach. Issues regarding the efficiency of iPSC differentiation 
towards the haematopoietic lineage also need addressing. On the other hand, in diseases 
where the number of HSC is compromised, iPSCs could provide a ready source of corrected 
cells. ZFNs have been used to correct various types of chronic granulomatous disease (CGD) by 
introducing five different functional genes into the AAVS1 ‘safe harbour’ in iPSCs generated 
from peripheral HSCs. Using in vitro myeloid differentiation, normal granulocytes were 
generated from the corrected iPSCs80. Provirus-free iPSCs resulting from methods in which no 
transgene integration events are required have been generated81. Such iPSCs overcome 
concerns related to insertional mutagenesis and spurious transgene expression, and are 
preferred for clinical application. Provirus-free iPSCs have been generated from a SCID-X1 
patient, and the genetic defect corrected utilizing TALENs82. These iPSCs retained their 
differentiation potential into NK cells, which expressed mature cell markers and had the 
correctly spliced IL2RG. This provided the first evidence of gene repair of SCID-X1 patient iPSCs 
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resulting in regeneration of mature lymphoid cells in vitro. For radiosensitive SCID, ZFNs were 
utilized to correct a mutation on Prkdc gene in primary mouse fibroblasts and iPSCs83. The 
corrected cells retained their potential to differentiate into functional T-cells in vitro, 
overcoming the developmental block. 
Even though gene editing in the context of PIDs is not yet ready to be applied in a clinical 
setting, it already offers valuable tools to study and model immune disorders at the cellular 
level. With CRISPR-Cas9, zygote injections can be done in a one-day procedure generating gene 
modified mice in less than 4 weeks84. NSG mice have been efficiently manipulated in this way85. 
Similarly, a rat model of SCID-X1 has been generated using ZFNs86. Additionally, endonucleases 
have been used to generate knockout models in animals previously unamenable to efficient 
genetic modification. These include: rabbits with IL2RG, RAG1, or RAG2 knockout87–90; hamsters 
with STAT2 knockout91; and monkeys with RAG1 knockout92. 
 
HAEMOPHILIA  
Haemophilia is a group of inherited bleeding disorders that affect the blood clotting process. 
This deficit is most often caused by mutations in genes coding for either clotting factor VIII 
(haemophilia A) or factor IX (haemophilia B), two crucial components of the blood coagulation 
cascade. People with haemophilia often experience internal bleeding into knee, hip, elbow and 
ankle and subsequent joint disease. Current care for haemophilia involves life-long infusions of 
clotting factors. Although highly effective at disease management, clotting factors are short-
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lived in circulation. This necessitates intravenous delivery at least 2-3 times per week, which is 
both invasive and expensive93. Alternatively gene therapy, via transfer of a normal copy of F8 or 
F9 gene (encoding FVIII and FIX), may enable permanent correction and stable endogenous 
expression. Estimates suggest that an increase of only 1% in plasma FVIII or FIX levels would be 
therapeutic and encouraging results have been obtained by AAV-vector mediated gene 
transfer94,95. 
Genome editing using programmable nucleases has also shown promise by allowing in situ 
targeting of haemophilia A and B. For haemophilia B, where mutations span across the entire 
coding region of human F9 (hF9) gene, HDR has been demonstrated by direct injections of 
AAV8-ZFNs and a corrective cDNA (promoterless exons 2-8 bearing a splice acceptor and a poly 
A signal flanked by homology arms) into livers of neonatal96 and adult humanized haemophilic 
mice97. In neonatal mice the level of gene repair was sufficient to correct clotting times, and 
partial hepatectomy showed stable genome modification, as levels of FIX were stable in the 
genome-edited liver. In sharp contrast, episomal AAV F9 transgene delivery could not overcome 
partial hepatectomy and FIX levels decreased to almost background levels, highlighting the 
advantage of gene editing96. Analyses in adult hF9 mice showed sustained expression of human 
FIX, averaging 23% of normal levels at week 6097. 
In a novel strategy, ZFNs were utilised for targeted integration of promoterless F8 and F9 
therapeutic transgenes within the highly expressed albumin gene98. The albumin gene is 
expressed at high levels in liver cells and loss of its expression from a few percent of cells does 
not appear to be detrimental. This study demonstrated AAV8-ZFN mediated long-term 
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expression of both human FVIII and FIX at therapeutic levels in haemophilia A and B mouse 
models, respectively98 and is progressing towards clinical application. This highlights that 
certain genomic sequences, such as the albumin locus, are both permissive and amenable for 
transgene integration. In this context it is worth mentioning a parallel study, which 
demonstrated nuclease-free, AAV-vector mediated targeting of the albumin locus to drive 
expression of FVIII and FIX in new born and adult mice. The animals expressed levels of clotting 
factor that were between 7-20% of normal99.  
Efforts to re-introduce F8 in haemophilia A have been more challenging. Such an approach has 
primarily been limited by the large size (7 Kb) of its cDNA, inefficient protein production and 
complex mutations, comprising mostly of large inversions and duplications. Among the 
genotypes that result in haemophilia A, two different types of chromosomal inversions 
involving a portion of F8 gene are most frequent, accounting for 50% of cases. An initial study 
using TALENs led to correction of an inversion mutation in an iPSC model, establishing proof-of-
concept100. Building up on this, a separate study demonstrated correction of a ~600 Kb 
inversion using CRISPR-Cas9 system in iPSCs derived from haemophilia A patients101. This was 
achieved by using Cas9 nucleases with target sites on either side of the inversion. Corrected 
iPSC colonies were clonally expanded before differentiating into epithelial cells, which 
produced FVIII protein in vitro. Transplantation of corrected endothelial cells rescued injury 
mortality in haemophilic mice in a short-term experiment101. 
Haemophilia gene therapy is a forerunner in the field, with promising clinical development 
using safer viral vectors. Although the genome editing strategies outlined here are still under 
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development and currently lack safety validation, they can be combined with existing 
advancements such as AAV-vector mediated delivery to the liver to further clinical application. 
Furthermore, manipulation of the albumin locus may allow for this condition to be treated in 
the absence of nucleases, and the locus could also be used as a ‘safe harbour’ for expression of 
other secreted proteins99.  
 
CONCLUSION 
The past few years have seen notable demonstrations of genome editing being applied across a 
multitude of diseases. Whilst the application of nucleases holds significant therapeutic promise, 
optimum progress can only be achieved by examining the advancement of gene editing 
holistically. A number of ubiquitous challenges need to be considered, mostly relating to 
efficacy of genome editing at the target sequence, safety concerns related to nuclease-
associated off-target effects and delivery of gene editing tools. 
Editing efficiency is dependent upon the DNA repair process being relied upon. In instances 
where the desired effect can be achieved by NHEJ, the correction will most likely occur at a 
relatively high frequency as NHEJ is the major repair pathway in mammalian cells, although the 
usefulness of this approach may be limited by the stochastic nature of the Indels being formed. 
As discussed earlier, NHEJ has been used to mediate disruption of coding and regulatory 
sequences, targeted deletions of exons or large intervening sequences and disruption of splice 
sites. Methods that can predict and evaluate micro-homology sites can be used to bias the 
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repair towards frameshift mutations in protein coding sequence102. This would partially address 
the potential reduction in efficiency caused by micro-homology-mediated end joining, a 
secondary end-joining pathway with a bias for in-frame deletions103. 
Precise HDR-based locus alterations allow targeted insertion or in situ correction of mutated 
DNA sequence, which are suitable for a large subset of disease-causing mutations. However, 
they are reliant upon homologous recombination, which is normally limited to S and G2 phases 
of the cell cycle, requires a DNA template and inherently occurs at lower frequencies. HDR-
based strategies may also require enrichment and expansion of corrected cells, normally 
restricted to ex vivo approaches. While ex vivo manipulation may be possible in diseases like 
those affecting bone marrow HSCs, it would limit applications in diseases with multi-organ 
involvement or those where transplantation is not an option. Further progress into enabling 
HDR with higher efficacy would therefore be beneficial. In this respect, a recent report has 
demonstrated that it may be possible to transiently activate HDR in G1 cells by restoring 
BRCA1-PALB2 interaction104, possibly facilitating HDR genome-editing in quiescent cells. 
Specificity of genome editing is one of the major safety concerns for translational research. 
Owing to sequence similarities within the genome, endonucleases can cleave and modify off-
target regions that are distinct from the site of interest. Off-target effects can lead to unwanted 
genetic modifications causing cellular stress, functional impairment or enhancement, and 
oncogenicity, all of which could have detrimental effects clinically105. Considerable work is being 
undertaken to increase fidelity through better design of nuclease components, which has led to 
improved variants such as megaTALs106, dead Cas9-Fok1 fusion nucleases107, Cas9 nickases108 
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and Cas9 nucleases with truncated guide RNAs109. Furthermore, screens of bacterial strains 
have led to discovery of several alternative Cas9-nucleases with varying specificities110–113. 
More recently, Cpf1, a prominent CRISPR variant that requires a shorter RNA and generates a 
staggered cut which could improve HDR, has also been described114. All of these variants 
highlight the progress in the field but still require extensive examination prior to their 
application in a translational research setting. Specificity of modification can also be helped by 
careful target site selection and use of delivery methods that would allow for efficient but 
transient expression of nucleases. New methods, such as GUIDE-seq115 and BLESS116, have also 
been developed for unbiased evaluation of off-target modifications on a genome-wide scale.  
The final challenge pertains to the delivery of gene editing reagents including nucleases and a 
donor template in case of HDR. A variety of delivery approaches are being explored depending 
on cell types to be targeted. Cells that can be cultured and engrafted under ex vivo conditions 
are amenable to delivery via nucleic acids, proteins and viral vector systems; mRNA and protein 
delivery of the nucleases are now well-established procedures. However, for in vivo gene 
editing applications the most promising delivery systems are viral vectors. Both integrating and 
non-integrating viral vector systems have been explored in this context, although the latter are 
favoured due to their safety profile. In particular, AAV vectors, with a wide range of serotypes 
and ability to transduce a variety of tissue types are promising candidates. However, AAV 
vectors are restricted by their small packaging capacity, which poses challenges for large 
nuclease proteins such as TALENs or Cas9.  
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Despite the outlined challenges, genome editing is advancing at fast pace, with continued focus 
on pioneering and improving strategies. The successful use of ZFNs targeting CCR5, the co-
receptor necessary for HIV to infect T-cells, to control AIDS, remains the single demonstration 
of gene-editing in a therapeutic setting117, but will be quickly followed by others. Our 
developing understanding of programmable nucleases and DNA repair, coupled to general 
progress in regenerative medicine and knowledge of inherited disease pathophysiology, should 
warrant exciting outcomes from therapeutic genome editing, which we could only dream of in 
the nineties118 –  we look forward to the next twenty years. 
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Table 1 Therapeutic gene editing approaches applied in selected monogenic diseases 
Disease Nuclease Gene editing strategy Nuclease delivery 
route
Experimental model 
Cystic Fibrosis (CF) ZFNs HDR-mediated cDNA knock-in (4.5 Kb) Plasmid transfection Human bronchial and CF tracheal epithelia22
HDR of ΔF508 mutation using plasmid donor Plasmid transfection iPSCs26
TALENs HDR of ΔF508 mutation using short DNA fragments Plasmid electroporation 
(Amaxa) 
iPSCs27
Cas9 HDR-mediated cDNA knock-in Plasmid transfection Stem cell organoids23
HDR of ΔF508 mutation using piggyBac transposon Plasmid electroporation 
(Lonza) 
iPSCs28
Duchenne Muscular 
Dystrophy (DMD) 
MGNs HDR with 4.2 Kb cDNA Lentiviral transduction Immortalised patient myoblasts38
ZFNs Excision of exon 51 to restore the reading frame 
(applicable to 13% of patients) 
Plasmid electroporation 
(Gene Pulsar X-Cell) 
Immortalised patient myoblasts40 
TALENs Exon 45 skipping by disruption of splice acceptor, 
NHEJ restoration of reading frame, HDR-mediated 
exon 44 cDNA knock-in 
Plasmid electroporation 
(Neon Life Technologies) 
Patient fibroblasts or iPSCs39
Cas9 Excision of exons 45-55 restoring the reading frame 
(applicable to 62% of patients) 
Plasmid electroporation 
(Gene Pulsar X-Cell) 
Immortalised patient myoblasts40 
HDR using a ssODN donor Cas9 mRNA injection Mdx zygote43
Exon 45 skipping by disruption of splice acceptor, 
NHEJ restoration of reading frame, HDR-mediated 
exon 44 cDNA knock-in 
Plasmid electroporation 
(Neon Life Technologies) 
Patient fibroblasts or iPSC39
Sickle Cell Anaemia 
(SCA) and β-
Thalassemia 
ZFNs HDR using plasmid donor Plasmid electroporation 
(Amaxa) 
SCA-patient iPSCs70
HDR using IDLV/ssODN donor ZFN mRNA electroporation 
(Harvard apparatus) 
Healthy donor and SCA-patient CD34+ cells66
HDR using plasmid donor Plasmid electroporation β-thalassemia-patient iPSCs67
NHEJ-mediated disruption of BCL11A enhancers for 
upregulation of HbF 
mRNA transfection 
(BTX device/ MaxCyte) 
Mobilized human (adult) CD34+ HSCs74
40 
 
TALENs HDR-mediated full-length cDNA knock-in Plasmid electroporation 
(Lonza) 
K562 cell line65
HDR using piggyBac transposon Plasmid electroporation 
(Amaxa*) 
β-thalassemia-patient iPSCs68, SCA-patient 
iPSCs*71 
NHEJ-mediated disruption of BCL11A enhancers for 
upregulation of HbF 
mRNA transfection 
(BTX device/ MaxCyte) 
Mobilized human (adult) CD34+ HSCs74
Cas9 HDR using piggyBac transposon Plasmid electroporation 
(Lonza) 
β-thalassemia-patient iPSCs68,69
NHEJ-mediated disruption of BCL11A enhancers for 
upregulation of HbF 
Lentiviral transduction HUDEP-2 (immortalised human CD34+) and 
CD34+ HSPCs75 
Primary immune 
deficiencies (PIDs) 
ZFN HDR-mediated cDNA knock-in at IL2RG using IDLV 
donor 
IDLV ZFN transduction K562, mouse embryonic stem cells and 
CD34+ cells77 
HDR-mediated knock-in at AAVS1 using CGD 
minigene plasmid donor 
ZFN mRNA (Lonza) CGD-patient iPSCs80
HDR of Prkdc point mutation using plasmid donor Plasmid transfection, 
electroporation (Lonza) 
RS-SCID mouse primary fibroblast, iPSCs83 
TALENs HDR-mediated cDNA knock-in (exons 5-8) at IL2RG
using IDLV donor 
ZFN mRNA electroporation 
(Lonza) 
Healthy/SCID-X1 donor CD34+ cells78 
HDR-mediated cDNA knock-in at IL2RG using plasmid 
donor 
Plasmid electroporation 
(Nepa Gene) 
Jurkat cells79
HDR of a splice-site mutation in IL2RG using plasmid 
donor 
Plasmid electroporation 
(Lonza) 
SCID-X1 patient iPSCs82
Haemophilia ZFN HDR at hF9 using AAV-8 donor AAV-8 ZFN transduction Humanised haemophilia B neonatal96, adult 
mice97 
HDR-mediated insertion of F8 and F9 cDNA within 
Albumin locus using AAV-8 donor 
AAV-8 ZFN transduction Humanised haemophilia A and B adult 
mice98 
NA HDR-mediated insertion of F9 cDNA within Albumin 
locus using AAV-8 donor 
N/A New-born and adult haemophilia B mice99
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TALENs NHEJ-mediated correction of 140 Kb inversion in F8
gene 
Plasmid electroporation Haemophilia A-patient iPSCs100
Cas9 NHEJ-mediated correction of 140 Kb and 600 Kb 
inversions in F8 gene 
Cas9 protein and in vitro 
transcribed gRNA 
electroporation (Neon Life 
Technologies) 
Haemophilia A-patient iPSCs101
 
Abbreviations: CGD (chronic granulomatous disease), HDR (homology-directed repair), IDLV (Integration-deficient lentiviral vector), iPSCs (induced pluripotent stem cells), 
MGNs (Meganucleases), NA (not applicable), NHEJ (non-homologous end-joining), RS-SCID (radiosensitive severe combined immunodeficiency), ssODN (single-stranded 
oligonucleotide), TALENs (Transcription activator-like effector nucleases), ZFNs (Zinc finger nucleases) 
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Figure Legend 
Figure 1 
 Overview of therapeutic gene editing  
(a) DNA repair pathways for the resolution of a double stranded break (DSB). A nuclease is targeted towards a defined genomic locus, introducing a DSB. 
This may undergo one of two major repair pathways known as non-homologous end joining (NHEJ) or homology directed repair (HDR), depending upon cell 
cycle stage and availability of a DNA donor template. NHEJ is an error prone mechanism, which causes small insertions or deletions (Indels) upon ligating 
the ends of the DNA break. HDR is a precise mechanism which repairs the break by using a homologous donor template.  
(b) Functional gene editing strategies using DNA repair pathways. 1) NHEJ can be used to disrupt genomic sequences as a consequence of Indels. This can 
cause frameshift mutations leading to an early stop codon (or restoration of the reading frame by splice site disruption). 2) NHEJ can mediate targeted 
deletions. This requires generation of DSBs on both sides of the target genomic sequence, which then deletes the intervening sequence while NHEJ re-joins 
the DNA ends. 3) HDR can be used to correct a specific mutation by introducing a nuclease-mediated DSB (in proximity to the target site) in the presence of 
a homologous donor DNA containing corrective sequence. Upon recombination, the repair template corrects the mutated locus. 4) Likewise, by supplying 
exogenous DNA on the donor template flanked between regions of homology, HDR can be used to mediate targeted gene insertion or knock-in. 
(c) Schematic diagram comparing ex vivo and in vivo approaches. In vivo approaches involve direct transfer (denoted by the syringe) of genome editing 
reagents such as programmable nucleases and donor templates to the human body. In this instance, two prominent gene transfer agents, viral vectors and 
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liposomes are shown. Ex-vivo is centred on correction of the genetic defect outside of the body. This is a staged-approach whereby: 1) Patient cells are 
obtained. 2) Gene editing is performed in vitro. This involves delivery of nucleases on their own or concomitantly with repair template. The patient cells can 
be programmed into induced pluripotent stem cells (iPSCs) before or after gene editing. Once corrected, iPSCs may be differentiated into cell types of 
interest. 3) The genetically corrected cells are characterized and expanded. 4) The corrected cells are then re-grafted back into the patient through 
autologous transplantation.  
 

